Medicine and Dentistry
Patient
100%
Clear Cell Renal Cell Carcinoma
96%
Therapeutic Procedure
51%
Combination Therapy
47%
Neoplasm
46%
Neoadjuvant Chemotherapy
32%
Immunotherapy
32%
Inpatient
27%
Muscle Invasive Bladder Cancer
25%
Transitional Cell Carcinoma
25%
Survival
24%
Malignant Neoplasm
24%
Immune Checkpoint Inhibitor
24%
Urothelial Cancer
21%
Cisplatin
21%
Prostate Cancer
21%
Systemic Therapy
20%
Programmed Death-Ligand 1
20%
Biological Marker
20%
Tyrosine-Kinase Inhibitor
19%
Protein Tyrosine Kinase
18%
Overall Survival
18%
Vasculotropin Receptor
17%
Analysis
17%
Nivolumab
17%
Cystectomy
17%
Meta-Analysis
16%
Pembrolizumab
14%
Bladder
14%
Bladder Cancer
13%
Immunocompetent Cell
12%
Disease
12%
Metastatic Colorectal Cancer
12%
Kidney Metastasis
11%
Gene Expression Profiling
10%
Liquid Biopsy
10%
Oncology
10%
Disease Burden
10%
Ipilimumab
10%
Enfortumab Vedotin
10%
Randomized Clinical Trial
10%
Clinical Trial
10%
Chemotherapy
10%
Phosphotransferase
9%
Surgery
9%
Immune Checkpoint Blockade
9%
Arm
8%
Cisplatin
8%
Metastatic Carcinoma
8%
Clear Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
40%
Immunotherapy
34%
Renal Cell Carcinoma
32%
Transitional Cell Carcinoma
30%
Cisplatin
29%
Protein Tyrosine Kinase Inhibitor
29%
Protein Tyrosine Kinase
28%
Vasculotropin Receptor
28%
Immune Checkpoint Inhibitor
28%
Neoplasm
23%
Survival
23%
Malignant Neoplasm
16%
Overall Survival
16%
Renal Cell Carcinoma
16%
Nivolumab
14%
Muscle Invasive Bladder Cancer
13%
Pembrolizumab
12%
Kidney Metastasis
11%
Atezolizumab
10%
Prostate Cancer
10%
Diseases
10%
Toxicity
9%
Drug
9%
Bladder Cancer
8%
Axitinib
7%
Platinum
7%
Clinical Trial
7%
Doxorubicin
7%
Biological Marker
6%
Melanoma
6%
Phase II Trials
6%
Progression Free Survival
5%
Prednisone
5%
Vinblastine
5%
Methotrexate
5%
Guadecitabine
5%
Lung Cancer
5%
Solid Malignant Neoplasm
5%
Congestive Heart Failure
5%
Ipilimumab
5%
Castration Resistant Prostate Cancer
5%
Pancreatitis
5%
Prospective Study
5%
RNA-Sequencing
5%
Hepatotoxicity
5%
Bicalutamide
5%
Abiraterone
5%
Enfortumab Vedotin
5%
Biological Marker
5%
Everolimus
5%